Role of Herceptin® in primary breast cancer: Views from North America and Europe

Oncology

Volumn 61, Issue SUPPL. 2, 2001, Pages 83-91

  Leyland Jones, Brian ^a   Smith, Ian ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Clinical trials; HER2; Herceptin ; Neoadjuvant therapy; Primary breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PLATINUM DERIVATIVE; RAZOXANE; RECEPTOR SUBTYPE; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; TAXOID; TUMOR MARKER; TUMOR PROTEIN;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERANCE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADULT; AGED; BREAST TUMOR; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG INTERACTION; EUROPE; FEMALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NORTH AMERICA; PALLIATIVE THERAPY; PATHOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; EUROPE; FEMALE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NORTH AMERICA; PACLITAXEL; PALLIATIVE CARE; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RESEARCH DESIGN; SAFETY; SURVIVAL ANALYSIS; TAMOXIFEN; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034767155     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055406     Document Type: Conference Paper

References (41)

1. Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy
2. Estrogen-dependent, tamoxifen-dependent tumorigenic growth of MCF-7 cells transfected with HER2/neu
3. Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose-escalated and tailored FEC therapy
4. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial
5. Herceptin (H) and Navelbine (V) for HER2-positive metastatic breast cancer: A phase II study
6. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
7. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
8. Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer
9. Polychemotherapy for early breast cancer: An overview of the randomised trials
10. Tamoxifen for early breast cancer: An overview of the randomised trials
11. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2 by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study
12. What threshold for adjuvant therapy in older breast cancer patients?
13. Further evaluation of intensified and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
14. Improved disease-free survival (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer
15. Developments in chemotherapy of breast cancer
16. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
17. A pharmacokinetic (PK) study of Herceptin® administered with paclitaxel i.v. every 3 weeks
18. Pharmacokinetics of Herceptin® administered with paclitaxel every three weeks
19. Is there a growing role for endocrine therapy in the treatment of breast cancer?
20. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: Results of the Finnish protocol Pegase 04
21. The concordance between the Clinical Trials Assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin® pivotal trials
22. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
23. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)
24. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
25. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
26. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13
27. The predictive value of HER2 in breast cancer
28. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: What have we learned?
29. New strategies in the treatment of non-metastatic breast cancer
30. What can be expected from the next generation of adjuvant breast cancer treatment?
31. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
32. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
33. Annual hazard rates of recurrence for breast cancer after primary therapy
34. Final report: Weekly Herceptin and Taxol for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype (IHC) and gene amplification (FISH)
35. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
36. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
37. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
38. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomised clinical trial
39. First-line, non-hormonal, treatment of woman with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
40. Formestane: A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer
41. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody